the control group it was 2.2, 3.8, and 3.3, respectively. Conclusion: The new topical botanical lotion showed remarkable efficacy, with a high degree of patient satisfaction and improvement of their quality of life.
Efficacy and Safety of a Topical Botanical in
context of follicular microinflammation. These may result in follicular miniaturization, stem cell apoptosis, and perifollicular fibrosis [5] [6] [7] [8] [9] . AGA reportedly affects 3-6% of women aged <30 years, increasing to 29-42% in women aged ≥70 years [10] . The frequency is lower in Asian women compared with those of European descent. There are no published data on the frequency of AGA in African women [11] [12] [13] [14] [15] [16] . In females, most often, the frontal hair line is preserved and hair is lost diffusely over the parietal areas and the crown, producing what is called the female pattern hair loss [17, 18] . The female pattern hair loss occurs less often and to a lesser degree than in men. AGA may produce a considerable cosmetic disfigurement and may have a significant psychosocial impact [19] [20] [21] [22] .
The only FDA-approved treatment for female AGA is the topical androgen-independent hair growth stimulator minoxidil, in concentrations of 2 and 5% (FDA, 1992). Other topical treatments include the 5α-reductase inhibitor finasteride, topical estrogens, the prostaglandin analogues latanaprost, travoprost, or bimatoprost, and platelet-rich plasma (PRP). Among systematic treatments, 5α-reductase inhibitors, such as finasteride and dutasteride, minoxidil, and the androgen receptor antagonists cyproterone acetate and spironolactone are reported to be the most effective. There are also other therapeutic options described, such as laser hair combs, camouflage techniques, and surgical approaches [23] [24] [25] [26] [27] [28] .
Although much progress has been made, treatment of AGA, especially among females, remains challenging. A novel formula (CG210 ® ) based on onion, lemon, seed, and cocoa extracts has been approved as a treatment option for AGA. The aim of our study was to evaluate the efficacy and safety of this topical botanical lotion in females with AGA.
Materials and Methods
The design of the study was that of a randomized, single-blinded, vehicle-controlled study. During a 12-month period, 40 unselected women, clinically diagnosed with AGA, were recruited from the Hair Clinic of our Department. All patients were informed about the methods and aims of the study and gave their consent. The study was approved by the Ethics Committee of our hospital. Inclusion criteria were the following: female sex, age ≥18 years, clinical diagnosis of AGA regardless of pattern, and no treatment for AGA or history of other treatment for any reason that might affect the outcome during the previous 12 months. The participants were randomized (2: 1) in a single-blinded manner using simple randomization and were assigned to apply either the active lotion or the vehicle, twice daily, for 24 weeks. During the study period, they were not allowed to use any other active agent for AGA, including food supplements. Subjects were evaluated at 0, 12, and 24 weeks by clinical examination, standardized photographic documentation, quality of life evaluation (DLQI), and trichogram. Hair density was assessed by clinical evaluation and comparison of photographs. An improvement of ≤25% was assessed as mild improvement, >25 to ≤50% as moderate improvement, and ≥50% as great improvement. For the quality of life assessment, a validated Greek version of the DLQI was employed. For the trichogram, approximately 40 hairs were plugged from the occipital or vertex area of the scalp. The percentage of anagen, catagen, telogen, and dystrophic hairs was recorded. As an assessment tool for the efficacy of the treatment, the anagen to telogen ratio was used. At each visit, the participants were asked to grade their level of satisfaction with the treatment. Possible adverse events were recorded at each visit.
Statistical Analysis
The ratio of anagen to telogen hair count (anagen to telogen ratio) as well as the quality of life evaluation (DLQI), clinical evaluation, and self-assessment are summarized descriptively as medians and interquartile ranges (IQR) or percentages when appropriate. The primary endpoint of this study is the change of the anagen to telogen ratio from baseline (pre-treatment) to 24 weeks (posttreatment). Secondary endpoints are the change of the anagen to telogen ratio from baseline to 12 weeks as well as the changes in quality of life, clinical evaluation, and self-assessment from baseline to 24 weeks.
Nonparametric tests (the two-sample Wilcoxon rank-sum, the matched-pairs Wilcoxon signed-rank, and the Fisher exact test) that do not require normality were used for the statistical evaluations. Analysis was based on the total number of randomly assigned patients who had both baseline and at least 1 post-treatment measurement (intention-to-treat principle). Probability values of <0.05 were considered to be statistically significant. All statistical tests are two-sided. Stata software was used for all analyses (Stata Corp., College Station, TX, USA).
Results
Forty females with AGA were randomized (2: 1) to the intervention and control groups using simple randomization. Of them, 39 patients completed the study (26 assigned to the intervention and 13 to the control group); 1 patient was lost to follow-up. Patients' age ranged from 26 to 81 years (median: 57 years) and disease duration from 1 to 30 years (median: 9 years). At baseline, the two groups were different only in terms of self-assessment; it was worse for patients randomly assigned to the intervention group. The baseline data of the study population, by treatment group, are presented in Table 1 .
Clinical Evaluation
The clinical evaluation demonstrated an increased hair density in the majority of patients receiving the active lotion (great improvement in 2, moderate improvement in 23, and stable condition in 1 patient), while all the patients receiving the control lotion were evaluated by the physician as stable (p < 0.001 for any improvement) (Fig. 1) . No topical or systemic adverse reactions were reported during the study period.
Self-Assessment
The self-assessment score significantly increased from baseline to 6 months in the intervention group (2, 1-3; p < 0.001), but not in the control group (0, 0-0; p = 0.56). Accordingly, the change from baseline was significantly higher in the intervention group (p < 0.001; Table 2 ).
Quality of Life
The quality of life, as assessed with the DLQI, significantly improved in patients of the intervention group (-1, -2 to -1; p < 0.001), while it deteriorated in patients assigned to the control group (3, 0-4; p = 0.015; the higher the DLQI score the more quality of life is impaired). Ac- 163 cordingly, the change in quality of life (from baseline to 6 months) was in favor of the active treatment (p < 0.001; Table 2 ).
Anagen to Telogen Ratio
At 3 months, the anagen to telogen ratio significantly increased both for the intervention group (median change: 1.7, IQR: 0.9-2.3; p < 0.001) and for the control group (1.6, 1.6-1.7; p = 0.001). The magnitude of this increase did not differ between the two groups (p = 0.78; Table 2 ).
At 6 months, the anagen to telogen ratio was again statistically significantly increased from baseline both for the intervention group (3.8, 3.2-4.5; p < 0.001) and the control group (1.1, 1.0-1.2; p = 0.001). This time, however, the change from baseline was significantly higher in the intervention group (p < 0.001; Table 2 ), supporting the hypothesis that the intervention (i.e., botanical lotion) is effective.
Discussion
According to our results, almost all patients (25 out of 26) clinically improved after receiving the active lotion over a 24-week period. The anagen to telogen ratio significantly increased from 2.1 at baseline to 3.9 at 12 weeks, and to 6.0 at 24 weeks. The participants in the intervention group assessed themselves as having significantly improved from baseline to 6 months compared to the control group. The quality of life, as assessed with the DLQI, improved in patients of the intervention group, while it worsened in the control group. During the study period, no significant adverse events were reported.
The mechanism of action of this novel formulation appears to be multidimensional. Interestingly, it differs from the mechanism of action of the existing treatment options. It has been found to increase (up to 89.9%) Bcl-2, an anti-apoptotic protein that acts during the catagen phase of the hair cycle, hence prolonging the anagen phase and cell survival. Additionally, it downregulates inflammation in the scalp by increasing the number of Langerhans cells and mast cells in the perifollicular area, thus preventing follicular miniaturization and fibrosis Color version available online [29, 30] . Furthermore, it increases (up to 67%) perifollicular collagen, leading to a better implantation of the hair.
In a recent 12-week, multicenter, single-arm, open-label study in 56 male subjects with mild to moderate AGA, the safety and efficacy of a twice-daily regimen of 5% minoxidil foam used in combination with this novel botanical hair solution was evaluated. A significant improvement in scalp hair coverage and perception in as early as 4 weeks (p < 0.001) was reported by the investigators. Subject self-ratings were significant for improved hair growth and hair appearance in as few as 4 weeks (p < 0.05). The regimen was well tolerated, and subjects indicated a high degree of satisfaction [29] .
Another multicenter, single-arm, open-label study in 54 female subjects evaluated the safety and efficacy of a twice-daily regimen of 2% minoxidil solution used in combination with the new botanical hair solution for 12 weeks. Investigator ratings indicated significant improvement in hair growth and overall treatment benefits in as early as 6 weeks (p < 0.001). Subject self-ratings indicated significant satisfaction with hair volume and quality improvement at week 6 (p < 0.001). Subjects also indicated an increase in self-confidence and attractiveness at week 12 (p < 0.001) [30] .
A 12-month, randomized, double-blind, placebo-controlled trial using CG210 (the novel topical anti-hair loss product) in 20 AGA volunteers already using finasteride 1 mg for at least 3 years was also published. Hair diameters were assessed and compared for hair pattern improvement. The increase of hair diameter in the "finasteride 1 mg + topical CG210" group was 37.7% more than that in the "finasteride 1 mg + topical placebo" group (p = 0.002). No side effects were observed [31] .
In another open prospective study of 20 male patients with AGA, immunohistochemical analyses of scalp biopsies showed a significant increase in the cutaneous immune response after treatment: 73.9% increase in CD1A+
Langerhans cells (p = 0.003, paired t test), 41.7% increase in the cellular proliferation marker Ki-67+ (p = 0.012), and 89% increase in BCL-2+ anti apoptotic proteins (p = 001). The product was also found to be tolerable and safe [32] .
Our results are in agreement with the already published data concerning this new botanical lotion. In addition, we demonstrated an improvement of AGA in females, as indicated by the progressive increase of the anagen to telogen ratio in the trichogram. The anagen to telogen ratio is considered to be a valid indicator of the follicle activity and its restoration to normal appears to be a strong documentation of the efficacy of this new botanical. CG210 seems to be a novel, promising treatment of female AGA. It acts with an original triple mechanism, different from the already existing therapies. It is very safe. In our study, it showed clinical and laboratorial (trichogram) efficacy, with a high degree of satisfaction and improvement of patients' quality of life. The results were evident in 3 months and significantly different after 6 months compared to the control group. Long-term follow-up of the patients will clarify the duration of the result achieved. In conclusion, CG210 appears to be an effective and safe alternative to minoxidil topical treatment for AGA in females. Future studies, including comparison with minoxidil, may support its use as a first-line choice in the treatment of AGA.
